This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chan, J. K. Articles by Berek, J. S. Search for Related Content PubMed PubMed Citation Articles by Chan, J. K. Articles by Berek, J. S. Related Articles Related Correspondence

Impact of the Human Papilloma Vaccine on Cervical Cancer

John K. Chan, Jonathan S. Berek

From the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford Cancer Center, Stanford; and the Division of Gynecologic Oncology, University of California at San Francisco Comprehensive Cancer Center, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, School of Medicine, San Francisco, CA

Address reprint requests to Jonathan S. Berek, MD, MMS, Stanford University School of Medicine, Department of Obstetrics and Gynecology, 300 Pasteur Dr, HH333, Stanford, CA 94305; e-mail: jberek{at}stanford.edu

During the last decade, research progress on cervical cancer has elucidated the role of human papilloma virus (HPV) in the pathogenesis of cervical cancer. Clinical trials on the viral-like particle HPV vaccines have good safety profiles and promising efficacy in preventing genital warts, cervical neoplasia, and cervical cancer. The implementation of the HPV vaccine is a tremendous milestone in our effort toward preventing cervical cancers. However, screening programs will continue to serve as a critical component in prevention due to the limitations of the current vaccines. The greatest impact in cervical cancer incidence worldwide requires improved health care access to underserved areas. Advances are needed to develop single-dose, heat-stable, needle-free, and affordable formulations of the HPV vaccine to overcome the socioeconomic barriers associated with this disease.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Related Correspondence

• Low Affordability May Limit the Effect of Cervical Cancer Vaccination in Central and Eastern European Countries
  Pavol Zubor, Jan Danko, Karol Kajo, and Norbert Szunyogh
  JCO 2007 25: 5534-5537 [Full Text]

This article has been cited by other articles:

				G. Javitt, D. Berkowitz, and L. O. Gostin Assessing Mandatory HPV Vaccination: Who Should Call the Shots? J. Law Med. Ethics, June 1, 2008; 36(2): 384 - 395. [PDF]

				T. Bian, Y. Wang, Z. Lu, Z. Ye, L. Zhao, J. Ren, H. Zhang, L. Ruan, and H. Tian Human papillomavirus type 16 L1E7 chimeric capsomeres have prophylactic and therapeutic efficacy against papillomavirus in mice Mol. Cancer Ther., May 1, 2008; 7(5): 1329 - 1335. [Abstract] [Full Text] [PDF]

				G. A.V. Boulet, C. A.J. Horvath, S. Berghmans, and J. Bogers Human Papillomavirus in Cervical Cancer Screening: Important Role as Biomarker Cancer Epidemiol. Biomarkers Prev., April 1, 2008; 17(4): 810 - 817. [Abstract] [Full Text] [PDF]

				T. Ju, G. S. Lanneau, T. Gautam, Y. Wang, B. Xia, S. R. Stowell, M. T. Willard, W. Wang, J. Y. Xia, R. E. Zuna, et al. Human Tumor Antigens Tn and Sialyl Tn Arise from Mutations in Cosmc Cancer Res., March 15, 2008; 68(6): 1636 - 1646. [Abstract] [Full Text] [PDF]

				P. Zubor, J. Danko, K. Kajo, and N. Szunyogh Low Affordability May Limit the Effect of Cervical Cancer Vaccination in Central and Eastern European Countries J. Clin. Oncol., December 1, 2007; 25(34): 5534 - 5537. [Full Text] [PDF]

				S. A. Cannistra and W. P. McGuire Progress in the Management of Gynecologic Cancer J. Clin. Oncol., July 10, 2007; 25(20): 2865 - 2866. [Full Text] [PDF]